Have a personal or library account? Click to login
Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry Cover

Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry

Global Heart
Volume 15 (2020): Issue 1
By: Manlio F. Márquez,  Manuel A. Baños-González,  Milton E. Guevara-Valdivia,  Jorge Vázquez-Acosta,  Manuel O. de los Ríos Ibarra,  Julio A. Aguilar-Linares,  Marcelo Jiménez-Cruz,  Norberto Matadamas-Hernández,  Rocío Camacho-Casillas,  Reynaldo Magaña-Magaña,  Ulises Rojel-Martínez,  Marco A. Alcocer-Gamba,  Susano Lara-Vaca,  Humberto Rodríguez-Reyes,  Marco A. Islava-Gálvez,  Lidia E. Betancourt-Hernández,  Nicolás Reyes-Reyes,  Miguel E. Beltrán-Gámez,  Carlos Cantú-Brito,  Alberto Z. Baños-Velasco,  Pedro J. del Rivero Morfin and  J. Antonio González-Hermosillo  
Open Access
|Apr 2020

References

  1. 1Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016. DOI: 10.1093/eurheartj/ehw210
    Back to article
  2. 2Huisman MV, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014. DOI: 10.1016/j.ahj.2013.12.006
    Back to article
  3. 3Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012; 163. DOI: 10.1016/j.ahj.2011.09.011
    Back to article
  4. 4Lara-Vaca S, Cordero-Cabra A, Martínez-Flores E, Iturralde-Torres P. Registro Mexicano de Fibrilación Auricular (ReMeFa). Gac Med Mex; 2014.
    Back to article
  5. 5Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014. DOI: 10.2147/IJGM.S62819
    Back to article
  6. 6González-Hermosillo JA, Márquez MF, Ocampo-Peña S, Nombre del Comité Científico del Registro CARMEN-AF en. Diseño de un registro de fibrilación auricular y riesgo embólico en México: CARMEN-AF. Arch Cardiol Mex. 2016; 87. DOI: 10.1016/j.acmx.2016.11.003
    Back to article
  7. 7World Bank. World Bank: Country and Lending Groups. World Bank Data Website 2017.
    Back to article
  8. 8Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: The framingham heart study. Circulation; 2004. DOI: 10.1161/01.CIR.0000140263.20897.42
    Back to article
  9. 9Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857–67. DOI: 10.7326/0003-4819-146-12-200706190-00007
    Back to article
  10. 10Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med; 2011. DOI: 10.1056/NEJMoa1411087
    Back to article
  11. 11Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med; 2009. DOI: 10.1056/NEJMoa0905561
    Back to article
  12. 12Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med; 2011. DOI: 10.1056/NEJMoa1009638
    Back to article
  13. 13Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest; 2010; 138: 1093–100. DOI: 10.1378/chest.10-0134
    Back to article
  14. 14Suárez Fernández C, Castilla-Guerra L, Cantero-Hinojosa J, Suriñach JM, Acosta de Bilbao F, Tamarit JJ, et al. Satisfaction with oral anticoagulants in patients with atrial fibrillation. Patient Prefer Adherence; 2018; 12: 267–74. DOI: 10.2147/PPA.S152109
    Back to article
  15. 15Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol; 2017. DOI: 10.1016/j.jacc.2016.11.061
    Back to article
  16. 16Bassand J-P, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KAA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Eur Heart J; 2016. DOI: 10.1093/eurheartj/ehw233
    Back to article
  17. 17Corbalán R, Conejeros C, Rey C, Stockins B, Eggers G, Astudillo C, et al. Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile. Rev Med Chil; 2017. DOI: 10.4067/s0034-98872017000800963
    Back to article
  18. 18Mazurek M, Huisman M, Rothman K, Paquette M, Teutsch C, Diener H-C, et al. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. Thromb Haemost; 2017. DOI: 10.1160/TH17-08-0555
    Back to article
  19. 19González-Hermosillo J, Baños-González M, Guevara-Valdivia M, Vázquez-Acosta J, de los Ríos Ibarra M, Aguilar-Linares K, et al. Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registry. IJC Heart & Vasculature; 2019; 22: 117–122. DOI: 10.1016/j.ijcha.2018.12.017
    Back to article
DOI: https://doi.org/10.5334/gh.767 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Jan 14, 2019
Accepted on: Jan 23, 2020
Published on: Apr 10, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Atrial fibrillation,
embolic risk,
anticoagulation therapy,
antithrombotic treatment,
vitamin K antagonist,
direct oral anticoagulant,
Mexico

© 2020 Manlio F. Márquez, Manuel A. Baños-González, Milton E. Guevara-Valdivia, Jorge Vázquez-Acosta, Manuel O. de los Ríos Ibarra, Julio A. Aguilar-Linares, Marcelo Jiménez-Cruz, Norberto Matadamas-Hernández, Rocío Camacho-Casillas, Reynaldo Magaña-Magaña, Ulises Rojel-Martínez, Marco A. Alcocer-Gamba, Susano Lara-Vaca, Humberto Rodríguez-Reyes, Marco A. Islava-Gálvez, Lidia E. Betancourt-Hernández, Nicolás Reyes-Reyes, Miguel E. Beltrán-Gámez, Carlos Cantú-Brito, Alberto Z. Baños-Velasco, Pedro J. del Rivero Morfin, J. Antonio González-Hermosillo, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 15 (2020): Issue 1Next article